FDA Advisory Committee Recommends AstraZeneca's Truqap for PTEN-Deficient Prostate Cancer

summarizeSummary

AstraZeneca's Truqap received a strong recommendation from the FDA's Oncologic Drugs Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer, marking a significant step towards approval for a new targeted treatment.

check_boxKey Events

• ODAC Recommends Truqap

  The FDA's Oncologic Drugs Advisory Committee (ODAC) voted 7 to 1, with 1 abstaining, to recommend Truqap (capivasertib) for PTEN-deficient metastatic hormone-sensitive prostate cancer.

• Addresses Unmet Need

  Truqap, in combination with abiraterone and ADT, is positioned as the first and only targeted treatment combination to demonstrate benefit in this aggressive subtype of prostate cancer.

• Strong Clinical Data

  The recommendation is based on the CAPItello-281 Phase III trial, which showed a statistically significant 19% reduction in the risk of radiographic disease progression or death.

• Next Steps for Approval

  The FDA will consider the ODAC's feedback during its review of the supplemental New Drug Application (sNDA), with a regulatory application also under review in the EU.

auto_awesomeAnalysis

The overwhelming 7-1 vote by the FDA's Oncologic Drugs Advisory Committee (ODAC) for Truqap in combination therapy for PTEN-deficient metastatic hormone-sensitive prostate cancer is a highly positive development. This recommendation, based on strong Phase III trial data showing a significant reduction in disease progression, addresses a critical unmet need for patients with this aggressive form of prostate cancer. While not a final approval, ODAC recommendations are typically strong indicators of future FDA action, positioning Truqap as the first and only targeted treatment combination for this specific patient population. This further strengthens AstraZeneca's oncology pipeline and continues a recent trend of positive regulatory and clinical news for the company.